Inspirex™ Lung
Bioengineered human lung graft for life-saving transplantation
Inspirex lung technology advances a new approach to organ transplantation through bioengineered human lung grafts with whole organ functionality and anatomical compatibility.
PRESSING NEED
More lung grafts for transplant
The wait for a lung transplant is a race against time. Many patients spend years on the transplant waiting list while facing rejection, complications, or progressive disease before a donor organ becomes available.
Inspirex™ lung advances a potential human lung transplant alternative for patients with limited transplant options and ongoing organ shortages.
MEDICAL BREAKTHROUGH
Inspirex™ Lung
Generated through our xenogeneic cross-circulation platform, Inspirex™ Lung is a bioengineered lung graft for transplant with whole organ functionality and anatomical compatibility for clinical transplantation.
The platform supports ongoing research in xenogeneic lung transplant science, organ rehabilitation, and regenerative transplantation medicine.
IMPACT
Transforming the future of lung transplantation
Lung transplant volumes have increased only incrementally over the past two decades despite growing patient demand.
The availability of Inspirex™ Lung may help expand access to transplantation, increase the number of viable donor lungs, and reduce lung transplant waitlist mortality in the United States.
- Organ Procurement & Transplant Network/Scientific Registry of Transplant Recipients. Annual Data Report, 2024.
REFERENCES
- O’Neill JD, Guenthart BA, Kim J, Chicotka S, Queen D, Fung K, et al. Cross-circulation for extracorporeal support and recovery of the lung. Nat Biomed Eng. 2017; 1: 1-15.
- Guenthart BA, O’Neill JD, Kim J, Queen D, Chicotka S, Fung K, et al. Regeneration of severely damaged lungs using an interventional cross-circulation platform. Nat Commun. 2019;10: 1-16.
- Hozain AE, Tipograf Y, Pinezich MR, Cunningham KM, Donocoff R, Queen D, et al. Multi-day maintenance of extracorporeal lungs using cross-circulation with conscious swine. J Thorac Cardiovasc Surg. 2019; 159: 1640-1653.
- Hozain AE, O’Neill JD, Pinezich MR, Tipograf Y, Donocoff R, Cunningham KM, et al. Xenogeneic cross-circulation for extracorporeal recovery of injured human lungs. Nat Med. 2020; 26:
1102-1113. - O’Neill JD, Guenthart BA, Hozain AE, Bacchetta M. Xenogeneic support for the recovery of human donor organs. J Thorac Cardiovasc Surg. 2022; 163: 1563-1570.
- Guenthart BA, O’Neill JD, Bacchetta M. Cannulation strategies in ex vivo lung perfusion. ASAIO Journal. 2022; 68(11): 222.
- Wu WK, Guenthart BA, O’Neill JD, Hozain AE, Tipograf Y, Ukita R, et al. Technique for xenogeneic cross-circulation to support human donor lungs ex vivo. J Heart Lung Transplant. 2023; 42(3):
335-344. - Wu WK, Stier MT, Stokes JW, Ukita R, Patel YJ, Cortelli M, et al. Immune characterization of a xenogeneic human lung cross-circulation support system. Sci Adv. 2023; 9(13): 1-13.
- Tracy KM, Harris TR, Petrovic M, Cortelli M, Tucker W, François S, et al. Lung rehabilitation using xenogeneic cross-circulation does not lead to hyperacute rejection in a human lung transplantation model. J Heart Lung Transplant. 2025; 44(7): 1122-1134.
- Pinezich MR, O’Neill JD, Guenthart BA, Kim J, Vila OF, Ma SP, et al. Theranostic methodology for ex vivo donor lung rehabilitation. Med. 2025; 6(7): 100644.